FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093537475> ?p ?o ?g. }

• W2093537475 abstract "The objective of this study was to challenge the activity of a promising intravesical drug (gemcitabine), administered at an intensive regimen (2,000 mg twice a week for 6 weeks) in treatment naïve CIS of the bladder and to observe side-effects. The statistical design was conceived to provide sufficient information through the enrollment of a low number of patients.Primary, secondary, and concurrent CIS with no prior intravesical therapy were eligible. Treatment schedule: 2000 mg gemcitabine in 50 ml saline, unbuffered, for 1 hour twice a week for 6 weeks. Complete response (CR) = negative cytology and negative cystoscopy + bladder mapping at 3 months. Failure (FA) = all other situations. Side-effects were recorded according to Common Terminology Criteria for Adverse Events (CTCAE).A 3-stage design. After testing the drug on 11 patients in the first stage, the trial had to be terminated if 3 or fewer CRs. After testing the drug on 21 patients in the first and second stages, the trial had to be terminated if 7 or fewer CRs. After testing the drug on 32 patients in all 3 stages, the drug was considered active in case of >12 CRs. Survival data up to 4 years from trial closure were collected.The study proceeded to stage II since 5/11 responded at stage I but it was stopped after including 18 patients due to side-effects; 6/18 had primary CIS, 7 had secondary CIS, and 5 concomitant CIS; 6/18 (33.3%) had grade 3 side-effects (4 G3 cystitis, 3 G3 leucopenia), leading to stopping the treatment in all 6 cases. CRs were observed in 8/18 patients (44.4%), FA in 10/18 (55.5%). Median overall survival (OS) was 44 months with a 4-year cancer-specific survival of 100%.Biweekly gemcitabine as first line treatment for CIS led to excess toxicity and suboptimal activity. Due to the peculiar statistical design, a negative response was generated enrolling a low number of patients. The absolute 4-year CSS suggests that no window of opportunity for disease cure may have been lost by assessing a new, non standard, treatment for CIS." @default.
• W2093537475 created "2016-06-24" @default.
• W2093537475 creator A5050171369 @default.
• W2093537475 creator A5067669304 @default.
• W2093537475 creator A5080212287 @default.
• W2093537475 creator A5081220576 @default.
• W2093537475 creator A5085447576 @default.
• W2093537475 date "2013-07-01" @default.
• W2093537475 modified "2023-10-03" @default.
• W2093537475 title "Phase II study of biweekly gemcitabine as first line therapy in CIS of the bladder: What does an aborted trial tell us?" @default.
• W2093537475 cites W1968626722 @default.
• W2093537475 cites W1995365262 @default.
• W2093537475 cites W2011925920 @default.
• W2093537475 cites W2020921800 @default.
• W2093537475 cites W2053155246 @default.
• W2093537475 cites W2055787946 @default.
• W2093537475 cites W2059804763 @default.
• W2093537475 cites W2069071140 @default.
• W2093537475 cites W2071015810 @default.
• W2093537475 cites W2075118413 @default.
• W2093537475 cites W2086276584 @default.
• W2093537475 cites W2091341372 @default.
• W2093537475 cites W2123309701 @default.
• W2093537475 cites W2159759416 @default.
• W2093537475 cites W2162756611 @default.
• W2093537475 cites W2165562791 @default.
• W2093537475 cites W74431517 @default.
• W2093537475 doi "https://doi.org/10.1016/j.urolonc.2011.03.011" @default.
• W2093537475 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21550828" @default.
• W2093537475 hasPublicationYear "2013" @default.
• W2093537475 type Work @default.
• W2093537475 sameAs 2093537475 @default.
• W2093537475 citedByCount "2" @default.
• W2093537475 countsByYear W20935374752015 @default.
• W2093537475 countsByYear W20935374752017 @default.
• W2093537475 crossrefType "journal-article" @default.
• W2093537475 hasAuthorship W2093537475A5050171369 @default.
• W2093537475 hasAuthorship W2093537475A5067669304 @default.
• W2093537475 hasAuthorship W2093537475A5080212287 @default.
• W2093537475 hasAuthorship W2093537475A5081220576 @default.
• W2093537475 hasAuthorship W2093537475A5085447576 @default.
• W2093537475 hasConcept C126322002 @default.
• W2093537475 hasConcept C126894567 @default.
• W2093537475 hasConcept C141071460 @default.
• W2093537475 hasConcept C146357865 @default.
• W2093537475 hasConcept C151730666 @default.
• W2093537475 hasConcept C197934379 @default.
• W2093537475 hasConcept C2776694085 @default.
• W2093537475 hasConcept C2777793932 @default.
• W2093537475 hasConcept C2778769751 @default.
• W2093537475 hasConcept C2779384505 @default.
• W2093537475 hasConcept C2780035454 @default.
• W2093537475 hasConcept C2780258809 @default.
• W2093537475 hasConcept C2781413609 @default.
• W2093537475 hasConcept C71924100 @default.
• W2093537475 hasConcept C77411442 @default.
• W2093537475 hasConcept C86803240 @default.
• W2093537475 hasConcept C98274493 @default.
• W2093537475 hasConceptScore W2093537475C126322002 @default.
• W2093537475 hasConceptScore W2093537475C126894567 @default.
• W2093537475 hasConceptScore W2093537475C141071460 @default.
• W2093537475 hasConceptScore W2093537475C146357865 @default.
• W2093537475 hasConceptScore W2093537475C151730666 @default.
• W2093537475 hasConceptScore W2093537475C197934379 @default.
• W2093537475 hasConceptScore W2093537475C2776694085 @default.
• W2093537475 hasConceptScore W2093537475C2777793932 @default.
• W2093537475 hasConceptScore W2093537475C2778769751 @default.
• W2093537475 hasConceptScore W2093537475C2779384505 @default.
• W2093537475 hasConceptScore W2093537475C2780035454 @default.
• W2093537475 hasConceptScore W2093537475C2780258809 @default.
• W2093537475 hasConceptScore W2093537475C2781413609 @default.
• W2093537475 hasConceptScore W2093537475C71924100 @default.
• W2093537475 hasConceptScore W2093537475C77411442 @default.
• W2093537475 hasConceptScore W2093537475C86803240 @default.
• W2093537475 hasConceptScore W2093537475C98274493 @default.
• W2093537475 hasLocation W20935374751 @default.
• W2093537475 hasLocation W20935374752 @default.
• W2093537475 hasOpenAccess W2093537475 @default.
• W2093537475 hasPrimaryLocation W20935374751 @default.
• W2093537475 hasRelatedWork W1482414758 @default.
• W2093537475 hasRelatedWork W1528788323 @default.
• W2093537475 hasRelatedWork W1812067939 @default.
• W2093537475 hasRelatedWork W1969024997 @default.
• W2093537475 hasRelatedWork W2004454292 @default.
• W2093537475 hasRelatedWork W2030768983 @default.
• W2093537475 hasRelatedWork W2038587487 @default.
• W2093537475 hasRelatedWork W2040084516 @default.
• W2093537475 hasRelatedWork W2054076555 @default.
• W2093537475 hasRelatedWork W2055194877 @default.
• W2093537475 hasRelatedWork W2109815554 @default.
• W2093537475 hasRelatedWork W2129414319 @default.
• W2093537475 hasRelatedWork W2152520755 @default.
• W2093537475 hasRelatedWork W2395499508 @default.
• W2093537475 hasRelatedWork W274407797 @default.
• W2093537475 hasRelatedWork W2993899292 @default.
• W2093537475 hasRelatedWork W3000087360 @default.
• W2093537475 hasRelatedWork W3207200137 @default.
• W2093537475 hasRelatedWork W606431418 @default.
• W2093537475 hasRelatedWork W2015191990 @default.
• W2093537475 isParatext "false" @default.

• next